Podjetje za medicinsko tehnologijo, ki se osredotoča na razvoj inovativnih tehnologij za zgodnjo diagnozo raka, je danes objavilo rezultate novih raziskav. Klinična študija raka jeter je pokazala velik potencial novega biomarkerja LAM, ki temelji na metilaciji DNK, za odkrivanje hepatocelularnega karcinoma (HCC). Občutljivost odkrivanja je 95 % in specifičnost 97.5 %.
V tej študiji so bili zbrani osnovni vzorci 130 oseb, vključno z: 60 osebami z diagnozo hepatocelularnega karcinoma (stopnje I do IV), 30 osebami brez bolezni jeter, 10 osebami z diagnozo benigne bolezni jeter in 30 osebami z diagnozo raka dojke, kolorektalnega raka ali pljučnega raka. DNK smo ekstrahirali iz vzorca, DNK transformirali z bisulfitom in metilacijo DNK kvantificirali z uporabo platforme IvyGene. Po končanem zbiranju podatkov in analizi vseh vzorcev zaslepite vzorce, da izračunate učinkovitost preskusa.
A total of 57 of the 60 samples taken from patients with hepatocellular carcinoma were correctly identified, with an overall calculated sensitivity of 95%. The sensitivity difference between detecting stage I and stage IV hepatocellular carcinoma was small (range 89% to 100%). Of the samples taken from cancer patients other than liver cancer, 90% of breast cancer samples, 80% of kolorektalnega raka samples, and 90% of lung cancer samples were correctly identified as non-liver cancer, and the total calculated specificity was 87%.
